A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia

Published:2014-02-27 Issue:9 Volume:123 Page:1302-1308
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Byrd John C.¹,Pagel John M.²,Awan Farrukh T.³,Forero Andres⁴,Flinn Ian W.⁵,Deauna-Limayo Delva P.⁶,Spurgeon Stephen E.⁷,Andritsos Leslie A.¹,Gopal Ajay K.²,Leonard John P.⁸,Eisenfeld Amy J.⁹,Bannink Jeannette E.⁹,Stromatt Scott C.⁹,Furman Richard R.⁸

Affiliation:

1. Division of Hematology and Comprehensive Cancer Center, The Ohio State University, Columbus, OH;

2. Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA;

3. Division of Hematology-Oncology, Georgia Regents University, Augusta, GA;

4. University of Alabama at Birmingham, Birmingham, AL;

5. Oncology, Sarah Cannon Research Institute, Nashville, TN;

6. Department of Hematologic Malignancies, Nevada Cancer Institute, Las Vegas, NV;

7. Department of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, OR;

8. Department of Medicine, Weill Cornell Medical College, New York, NY; and

9. Emergent Product Development Seattle, LLC, Seattle, WA

Abstract

Key Points Otlertuzumab (formerly TRU-016) has modest single-agent activity in symptomatic treated and untreated CLL. Otlertuzumab demonstrates an acceptable safety profile, providing rationale for combination with other effective CLL therapies.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/9/1302/1379155/1302.pdf

Reference26 articles.

1. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.;Byrd;Blood,2005

2. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.;Tam;Blood,2008

3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.;Hallek;Lancet,2010

4. First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.;Eichhorst;Blood,2009

5. Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.;Woyach;J Clin Oncol,2013

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-CD37 CAR T cells: another arrow in the quiver;Blood;2024-09-12

2. PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansine;2023-11-16

3. Immunotherapeutic Strategies in Chronic Lymphocytic Leukemia: Advances and Challenges;Frontiers in Oncology;2022-02-21

4. CD37 expression in follicular lymphoma;Annals of Hematology;2022-02-16

5. Current state of CAR-T therapy for T-cell malignancies;Therapeutic Advances in Hematology;2022-01